Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Pediatric Lymphatic Malformations
NCT02335242Phase 2Completed
- Sponsor
- Stanford University
- Start
- May 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sildenafil in Lymphatic Malformation (LM), sponsored by Stanford University. Primary endpoint: Change in Lesion Volume at 20 weeks. Started May 2015; status: completed.
02
Drugs
sildenafil
03
Conditions
Lymphatic Malformation (LM)
Beyond the preview
Go deeper on NCT02335242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335242.